Optimising the number of cores for magnetic resonance imaging‐guided targeted and systematic transperineal prostate biopsy

BJU International - Tập 125 Số 2 - Trang 260-269 - 2020
Nienke L. Hansen1,2,3, Tristan Barrett1,4, Thomas Lloyd1,5, Anne Y. Warren1,6, Christina Samel7, Ola Bratt1,8, Christof Kastner1,2,5
1CamPARI Prostate Cancer Group, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK
2Christof Kastner, Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals, Hills Road Campus, Cambridge CB2 0QQ, UK and Nienke L. Hansen, CamPARI Prostate Cancer Group, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
3Department of Diagnostic and Interventional Radiology, Faculty of Medicine, University Hospital of Cologne, Medicine and University Hospital of Cologne, Cologne, Germany
4Department of Radiology, Cambridge University Hospitals, Cambridge, UK
5Department of Urology, Cambridge University Hospitals, Cambridge, UK
6Department of Pathology, Cambridge University Hospitals, Cambridge, UK
7Institute of Medical Statistics and Computational Biology (IMSB), University Hospital of Cologne, Cologne, Germany
8Department of Urology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

Tóm tắt

Objectives

To assess cancer detection rates of different target‐dependent transperineal magnetic resonance (MR)/ultrasonography (US) fusion‐guided biopsy templates with reduced number of systematic cores.

Patients and Methods

Single‐centre outcome of transperineal MR/US fusion‐guided biopsies of 487 men with a single target MR imaging (MRI) lesion, prospectively collected between 2012 and 2016. All men underwent transperineal targeted biopsy (TB) with two cores, followed by 18–24 systematic sector biopsies (SB) using the Ginsburg protocol. Gleason score ≥7 prostate cancer detection rates for two‐core TB, four‐core extended TB (eTB), 10‐ to 20‐core saturation TB (sTB) including cores from sectors adjacent to the target, and 14 core ipsilateral TB (iTB) were compared to combined TB+SB.

Results

Cancer was detected in 345 men and Gleason score 7–10 cancer in 211 men. TB alone detected 67%, eTB 76%, sTB 91% and iTB 91% of these Gleason score 7–10 cancers. In the subgroup of 33 men (7% of cohort) with an anterior >0.5 mL highly suspicious MRI lesion and a prostate volume ≤45 mL, four‐core eTB detected 31 of 32 cancers (97%) and all 26 Gleason score 7–10 cancers.

Conclusion

sTB detected Gleason score 7–10 cancer in 25% more of the men than a two‐core TB approach, and in almost as many men (91%) as the 20–26‐core combined TB+SB, while needing only 10–20 cores. A four‐core extended TB may suffice for large, highly suspicious anterior lesions in small or slightly enlarged prostates.

Từ khóa


Tài liệu tham khảo

MottetN van denBerghRC BiersEet al.EAU Guideline Prostate Cancer 2019. Available at:http://uroweb.org/guideline/prostate-cancer/. Accessed March 2019

10.1016/j.eururo.2018.05.035

Drost FH, 2019, Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer, Cochrane Database Syst Rev, 4, CD012663

10.1056/NEJMoa1801993

10.1016/S1470-2045(18)30569-2

10.1016/j.eururo.2018.11.023

10.1016/j.eururo.2017.02.026

10.1001/jama.2014.17942

10.1016/j.eururo.2014.08.077

10.1111/bju.13711

10.1111/bju.14049

10.1111/bju.14017

10.1016/j.urology.2016.11.017

10.1016/j.juro.2017.10.048

10.1111/bju.12750

10.1111/bju.12132

10.1016/j.eururo.2015.12.052

10.1148/radiol.2523081423

10.1016/j.juro.2013.12.006

10.1111/bju.12637

10.1111/bju.13971

10.1111/bju.13619

10.1016/j.eururo.2013.03.030

10.1016/j.eururo.2016.02.064

10.1097/01.pas.0000173646.99337.b1

10.1097/PAS.0000000000000530

10.1111/bju.14089

10.1007/s00345-015-1650-0

Wadhwa K, 2017, Transperineal prostate biopsies for diagnosis of prostate cancer are well tolerated: a prospective study using patient‐reported outcome measures, Asian J Androl, 19, 62, 10.4103/1008-682X.173453

10.1016/j.juro.2017.08.040

10.1111/bju.13859

10.1016/S0140-6736(16)32401-1

10.1007/s00330-016-4635-5

Greer MD, 2019, Interreader variability of prostate imaging reporting and data system version 2 in detecting and assessing prostate cancer lesions at prostate MRI, AJR Am J Roentgenol, 27, 1

10.1111/bju.12892